J&J Q4 ’17 Earnings Update

J&J hosted their Q4 ’17 earnings call and briefly discussed the diabetes business unit, including declining Invokana sales and the future of their diabetes device business. Notably, in response to analyst questions regarding potential diabetes divestitures, management was noncommittal.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.